- Clinical Trials
Our technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options.
We are developing gene therapies for patients with cancer and diabetes to bring new treatment options to large patient populations. Our lead product candidate, GPX-001, is designed to be administered in combination with other therapies, including targeted therapies and immunotherapies, for non-small cell lung cancer.
We have assembled a multidisciplinary team of executives and advisors with broad business experience in the biotech and pharmaceutical industries, and research and clinical experience at preeminent medical and academic institutions around the world. Our management team pairs an unmatched expertise with a knack for innovation in research.
At Genprex, we are committed to developing life-changing gene therapies for patients with cancer and diabetes through unique, innovative science. We are dedicated in our efforts to helping patients with limited or no treatment options to have access to new and advanced therapies to more effectively treat their disease.
Genprex’s President and Chief Executive Officer, Rodney Varner, will be delivering the company’s corporate presentation followed by a Q&A session with participants.
The 2020 Cell and Gene Meeting on the Mesa will be delivered in a virtual format over the course of five days where attendees will be able to watch company presentations on-demand, in addition to two live-streaming panels each day.
Gallagher’s appointment demonstrates the Company’s commitment to building a world-class intellectual property portfolio
Dr. Gannon will oversee and manage regulatory matters for the Company’s upcoming clinical trials, including its lead drug candidate in combination with Tagrisso® for which Fast Track Designation was received earlier this year.
We’re passionate about the work we’re doing to revolutionize the fight against cancer and diabetes. Whether you or somebody you know is afflicted by one of these diseases, you are a medical practioner interested in our treatment options, or you are an investor that has supported our fight, we want to keep you informed of our advancements. For up-to-the-minute company news delivered straight to your inbox, sign up for our email newsletter.